Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review

Hodgkin lymphoma (HL) is highly curable, with 5-year overall survival (OS) rates at ∼85% [1]. Thus, HL therapy aims to optimize disease control while minimizing risk of treatment late effects. Comp...